Cipla reported INR10.18B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Arca Biopharma USD 49.52M 2.58M Mar/2026
aTyr Pharma USD 10.01M 735K Mar/2026
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 15K 14K Mar/2026
Capricor Therapeutics USD 105.42M 182.42M Mar/2026
Cara Therapeutics USD 19.85M 883K Mar/2026
Cipla INR 10.18B 2.22B Mar/2026
Dr.Reddys Laboratories INR 11.2B 4.16B Jun/2026
Immunic USD 186.63M 171.15M Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sun Pharmaceuticals INR 97.71B 15.61B Mar/2026
TherapeuticsMD 523K 89K Jun/2024
UPL INR 59.75B 18.23B Mar/2026